Cutaneous leishmaniasis treated with miltefosine: A case series of 10 paediatric patients

Ayelet Ollech, Michal Solomon, Amir Horev, Shiran Reiss-Huss, Dan Ben-Amitai, Alex Zvulunov, Rivka Friedland, Vered Atar-Snir, Vered Pessach-Molcho, Aviv Barzilai, Shoshana Greenberger

    Research output: Contribution to journalArticlepeer-review

    3 Scopus citations


    Cutaneous leishmaniasis poses a therapeutic chal-lenge in the paediatric population. The aim of this study was to assess the efficacy and safety of miltefo-sine treatment for Old World cutaneous leishmaniasis in paediatric patients. A multicentre retrospective review of 10 children (≤ 18 years of age) with cutaneous leishmaniasis treated with miltefosine in Israel was performed. Mean ± standard deviation age at diagnosis was 9.1 ± 5.0 years. The Leishmania species diagnosed was L. tropica in 8 cases and Leishmania major in 2 cases. Mean ± standard deviation duration of treatment was 44.8 ± 20.6 days, with a mean follow-up period of 12.1 ± 17.1 months. Complete response was noted in 8 (80%) patients. Treatment failure was noted in 2 (20%) cases. Side-effects related to the medication were minimal. In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.

    Original languageEnglish
    Article numberadv00322
    Pages (from-to)1-5
    Number of pages5
    JournalActa Dermato-Venereologica
    Issue number18
    StatePublished - 1 Jan 2020


    • Amphotericin B
    • Leishmania ma-jor
    • Leishmania tropica
    • Leishmaniasis
    • Miltefosine
    • Sodium stibogluconate

    ASJC Scopus subject areas

    • Dermatology


    Dive into the research topics of 'Cutaneous leishmaniasis treated with miltefosine: A case series of 10 paediatric patients'. Together they form a unique fingerprint.

    Cite this